Neurenati Therapeutics

About Neurenati Therapeutics

Neurenati Therapeutics, based in Montreal, is a pioneering biotechnology company founded in 2020 by academic researchers Nicolas Pilon and Rodolphe Soret. The company is dedicated to developing a revolutionary treatment for Hirschsprung's disease, aiming to regenerate the enteric nervous system in affected patients, primarily young children, to improve intestinal functions and overall well-being.

Products & Services

NEU-001:A potential cure for Hirschsprung's disease administered via rectal enema, designed to regenerate the missing enteric nervous system in the colon of patients and enhance intestinal functions.

Specialties

Hirschsprung's disease treatment Enteric nervous system regeneration Rare disease therapies Neuro-gastroenterology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 1700000 MR: - FA: 1.7 Million FAN: 1700000	D: 2024-04-18 FD: 2024-04-18	2 investors
2	RT: Seed T: - FT: Seed	A: 1200000 MR: - FA: 1.2 million FAN: 1200000	D: 2024-02-29 FD: 2024-02-29	1 investors

Seed Latest

2024-04-18

$1.7M

2 investors (Pro only)

Seed 2024-02-29

$1.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Maxime Ranger

Serial Entrepreneur

LinkedIn (Pro only)

N

Nicolas Pilon

Expert in rare diseases and the development of neural crest cells

LinkedIn (Pro only)

R

Rodolphe Soret

Specialist in Neuro-Gastroenterology

LinkedIn (Pro only)

M

Meriam Kabbaj

Head of Development

M

Marie-Eve Bordeleau

Vice-President, Scientific Affairs

C

Christophe Mellon

Vice-President CMC

View 12 more team members with Pro

Unlock Full Team Directory

Recent News